Scientists report in Science Advances that a single-shot combined vaccine produced protective immune responses in animals. The research comes after several years in which influenza, COVID-19 and RSV circulated together and stressed health systems.
The team used a vaccine platform called CoPoP to deliver five viral proteins in one injection: three influenza proteins plus SARS-CoV-2 and RSV proteins. The formulation included immune-stimulating ingredients PHAD and QS-21 to boost potency. CoPoP attaches proteins to nanoparticles using histidine tags (his-tags) that bind cobalt ions.
Corresponding author Jonathan Lovell said the combined shot produced antibody responses similar to those from single-virus vaccines. Coauthor Bruce Davidson noted that many people skip recommended respiratory vaccines because it can be inconvenient, and a single annual shot could improve uptake. The researchers saw no evidence of immune interference but caution that further studies are needed before clinical use.
Difficult words
- vaccine — medicine given to prevent an infectionvaccines
- platform — system used to deliver vaccine or therapy
- formulation — mixture of ingredients in a vaccine
- antibody — protein made by the immune system
- nanoparticle — very small particle used in medicinenanoparticles
- histidine tag — short protein piece that binds metalshistidine tags
- immune interference — when immune reactions reduce vaccine effectiveness
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you be more likely to get a single annual combined vaccine for flu, COVID-19 and RSV? Why or why not?
- What advantages and concerns do you see for giving five viral proteins in one injection?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
New Oral Drug Candidate for Measles and Parainfluenza
Researchers identified a clinical candidate called GHP-88310 that inhibits orthoparamyxoviruses and tested it in animal models and human airway cultures. The compound showed broad once-daily oral activity and good tolerance in animals.